Drugs / BMD006
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06928922 | Feb 2025 → Feb 2027 expected | lung cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07307053 | Jan 2026 → Jan 2029 expected | high grade malignant neoplasm, metastatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMD006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06928922 ↗ |
| Modality | Messenger RNA (mRNA) | “BMD006 is an inhaled mRNA tumor-associated antigen dry powder vaccine” NCT06928922 ↗ |
| Route | Inhaled | “BMD006 is an inhaled mRNA tumor-associated antigen dry powder vaccine” NCT06928922 ↗ |